New Delhi, Feb 12 (IANS) Shorter, six‑month and all‑oral treatment regimens for multidrug‑resistant and rifampicin‑resistant tuberculosis (MDR/RR‑TB) are cost‑effective and deliver better health outcomes than longer regimens, an ICMR study said on Thursday.With shorter regimen, “for each additional Quality Adjusted Life Year (QALY) gained, the health system spends Rs 379 less per patient compared to the standard regimen, indicating better health outcomes at lower costs,” said the s…
Latest Central Tuberculosis Division News & Updates
New Delhi, Jan 12 (IANS) Delhi’s Intermediate Reference Laboratory (IRL), Tuberculosis Centre, has achieved a major milestone with its first certification from the Central Tuberculosis Division (CTD), Government of India, to conduct Drug Susceptibility Testing (DST) for two drugs, an official said on Monday. Bedaquiline (BDQ) and Pretomanid (Pa), which will be tested, are two key drugs used globally for the treatment of drug-resistant tuberculosis (DR-TB), the official said.This certification …